Galen Partners
Stamford, Connecticut-based Galen Partners is a healthcare growth equity firm founded in 1990. It has raised six funds totaling nearly $1 billion and invests in proven healthcare companies (revenues above $10M) across five verticals using a Collaborative Capital approach.
- Company typePrivate
- Founded1990
- HeadquartersStamford, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Galen Partners does
Galen Partners is a privately held, healthcare-exclusive growth equity investment firm founded in 1990 and headquartered in Stamford, Connecticut. The firm has raised six dedicated funds totaling nearly $1 billion in aggregate committed capital and has built a portfolio of more than 80 healthcare companies with an aggregate market value exceeding $10 billion. Galen is led by three Managing Directors (Philip Borden, David Jahns, Zubeen Shroff) supported by a CFO, two founding-era senior advisors, and a 15-member Special Investment Partner (SIP) bench of senior healthcare operators. The firm targets proven growth-stage healthcare companies with revenues above $10 million and EBITDA between $0 and $9 million, deploying capital through majority recapitalizations, growth equity, and buyouts across five verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.
The firm's core product is its "Collaborative Capital" approach, a service methodology that pairs equity capital with hands-on operating support in eight areas: growth strategy, recruiting and team-building, new customer introductions, operational improvements, forecasting and budgeting, M&A support, outsourced business development, and exit-value maximization. The SIP network functions as a deal-sourcing and operating-partner channel that generalist peers cannot easily replicate. Galen has no proprietary technology platform of its own; its technology exposure is through portfolio companies that include AI-enabled diagnostics (CDx's WATS3D), perinatal AI (PeriGen), digital health (Sharecare), medical image exchange (lifeIMAGE), and enterprise telehealth (historically InTouch Health, exited to Teladoc in 2020 for ~$600M).
Galen's revenue model is a traditional fund management business: management fees on committed or invested capital across its six funds, supplemented by lumpy carried interest tied to portfolio realizations such as the Pyxis/Cardinal Health exit, Taro Pharmaceutical's public listing, and the Teladoc Health acquisition of InTouch Health. Distribution and deal flow come from direct founder-to-founder outreach, the SIP network, and healthcare-specialized legal and financial advisors. The firm is not pursuing seed or early-stage healthcare deals and is exclusively a US-domestic investor.
Galen Partners firmographics
Firmographics- Name
- Galen Partners
- Legal name
- Galen Partners
- Website
- http://www.galen.com/
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Stamford, Connecticut-based Galen Partners is a healthcare growth equity firm founded in 1990. It has raised six funds totaling nearly $1 billion and invests in proven healthcare companies (revenues above $10M) across five verticals using a Collaborative Capital approach.
- Ownership category
- akta.pro rank
Galen Partners industry classification
Industry- Product category
- Healthcare Growth Equity / Venture Capital
- NAICS
- Other Insurance Funds (525190)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Galen Partners is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Galen Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Healthcare growth equity fund management: Galen raises dedicated healthcare-focused growth equity funds (six funds to date, totaling nearly $1 billion in committed capital since 1990) and invests capital into healthcare companies. Returns are generated through a combination of ongoing fund management activities and realized gains from portfolio company exits, IPOs, M&A, and recapitalizations.
- Operating support and value creation services: Beyond capital, Galen provides Collaborative Capital services — growth strategy, recruiting, customer introductions, operational improvements, M&A advisory and exit planning — which underpin the firm's value capture in portfolio company outcomes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Bespoke negotiated investments in healthcare growth companies with revenues >$10M and EBITDA between $0 and $9M. |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels5 records
Galen Partners product offering
Product offeringCore offering
Galen Partners is a healthcare-focused growth equity investment firm that raises dedicated funds from limited partners and invests growth-stage capital into US-headquartered healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. Beyond capital, the firm deploys a "Collaborative Capital" approach that bundles eight categories of hands-on operating support — growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization — into a bespoke investment structure tailored to each founder's needs. Galen has raised six dedicated funds totaling nearly $1 billion since 1990 and built a portfolio of more than 80 healthcare companies across Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.
Product overview
Galen Partners is a healthcare-focused growth equity investment firm (not a technology product company), founded in 1990 and headquartered in Stamford, CT. The firm's offering is a single platform — its "Collaborative Capital" investment approach — deployed across six dedicated funds totaling nearly $1 billion, which has built a portfolio of 80+ healthcare companies organized into five investment verticals: the Healthcare IT (e.g., Sharecare, lifeIMAGE, InTouch Health), Medical Technology (e.g., CDx Diagnostics, Tactile Medical, MiniMed), Outsourcing (e.g., Stericycle, MedAssets), Healthcare Services (e.g., Evolve Treatment Centers), and Specialty Products (e.g., SMP Pharmacy Solutions, Quotient) portfolio categories. Beyond capital, Galen's Collaborative Capital service methodology bundles operational support across growth strategy, team building, customer introductions, operational improvements, forecasting/budgeting, acquisitions, business development, and exit maximization. The firm's portfolio companies span proprietary AI-powered diagnostic platforms (CDx's WATS3D), digital health engagement platforms (Sharecare), perinatal AI monitoring (PeriGen), and clinical imaging interoperability (lifeIMAGE).
Differentiator
Problem solved
Functional benefit
Products and services
- Collaborative Capital Galen's flagship investment service methodology that combines growth equity capital with hands-on operating support across eight functional areas: growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization. Provided to founders and management teams of healthcare growth-stage companies.
- Galen Healthcare Growth Equity Funds Six dedicated healthcare-focused growth equity funds raised since 1990 totaling nearly $1 billion in committed capital. Investments target US healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million, organized across five investment verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products. To date, 80+ portfolio companies have been backed with over $10 billion in aggregate portfolio market value.
- Healthcare IT Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare IT companies including telehealth (InTouch Health), digital health platforms (Sharecare, Dakim BrainFitness), medical image exchange and clinical data networks (Life Image / lifeIMAGE), and perinatal AI clinical decision support (PeriGen). Target investments are US healthcare growth companies with revenues >$10M and EBITDA $0–$9M.
- Medical Technology Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in medical devices, diagnostics, and capital equipment, with portfolio companies including Cardiva Medical, SonaCare, DJO, ONI, Unisyn, CDx Diagnostics, Aperio, MiniMed, Pyxis, Tactile Medical (Tactile Systems), CryoLife, National Rehab Equipment, and Soteira.
- Outsourcing Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare outsourcing and services firms such as Consensys, Daou, Eduneering, Stericycle, MedAssets, and Chamberlin Edmonds.
- Healthcare Services Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare services and providers, with portfolio companies including Evolve Treatment Centers (adolescent behavioral health, acquired 2020), ParadigmHealth, IDC, Vitas, IMG, Lumenos, Qmed, Theratech, PET DRX Corp, and CBLPath.
- Specialty Products Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in specialty pharmaceuticals, fertility pharmacy, generic drugs, and consumer health products, with portfolio companies including SMP Pharmacy Solutions, Quotient (Quotient BioDiagnostics), JDS Pharmaceuticals, Nautilus Neurosciences, Acura Pharmaceuticals, SHPI, Vasogen, Vivus, Cambrooke, Ocular Sciences, Dow Pharmaceutical Sciences, and Taro Pharmaceuticals.
Quantifiable outcome
- Over $10 billion aggregate portfolio market value across 80+ companies
- +4 more outcomes
Companies that use Galen Partners
Customer profileNamed customers10 records
Segments8 records
Ideal customer profiles1 record
Galen Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature2 records
Galen Partners partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights5 records
Galen Partners competitors and assessment
Company assessmentBroad incumbents
- Arsenal Capital Partners: Private equity firm with a significant healthcare and specialty industrials franchise. Comparable to Galen in healthcare services and specialty products investing, though broader in sector mandate.
- General Atlantic: Large global growth equity investor with a meaningful healthcare practice. Comparable to Galen in growth-stage healthcare investing (e.g., backing Sharecare-adjacent businesses), though broader in scope and significantly larger in AUM.
Direct peers
- Welsh, Carson, Anderson & Stowe: One of the largest and longest-tenured healthcare-dedicated private equity/growth equity firms in the US. Directly comparable to Galen as a healthcare-only growth investor operating multiple funds and deploying capital across healthcare services, IT, and medical technology.
- New Mountain Capital: US growth equity firm with a sizable healthcare franchise (defense, health services, pharma services). Mirrors Galen's growth-stage mandate, collaborative operating model, and healthcare vertical orientation.
- Linden Capital Partners: US private equity firm exclusively focused on healthcare (healthcare services, MedTech, pharma services). Closely comparable to Galen's healthcare-only mandate and growth-stage investment focus.
- Cressey & Company: Healthcare-dedicated growth equity firm based in Nashville. Directly comparable to Galen in targeting mid-to-late growth-stage healthcare companies and providing operating partnership beyond capital.
- Avista Capital Partners: Healthcare-focused middle-market private equity firm. Similar to Galen in healthcare-only mandate and concentration in growth equity / recapitalization transactions across healthcare services and pharma.
- Health Velocity Capital: Healthcare-focused growth equity firm investing in health IT, services, and medical technology. Comparable to Galen in vertical specialization and growth-stage orientation, with a particular emphasis on healthcare IT.
- Aquiline Capital Partners: Private equity firm focused on financial services and healthcare. Comparable to Galen in growth-stage healthcare investing and providing operating support alongside capital.
- Ascension Ventures: Healthcare-dedicated venture and growth capital fund affiliated with Ascension Health. Comparable to Galen in healthcare-only mandate and growth-stage equity investing, though typically backed by a strategic health system LP base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Galen Partners social profiles
Digital presenceGalen Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Galen Partners leadership team
Management profileNumber of profiles
Profiles7 records
Galen Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Galen Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Galen Partners M&A and investment
M&A and investmentM&A2 records
Investments28 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Galen Partners
What does Galen Partners do?
Galen Partners is a healthcare-focused growth equity investment firm that raises dedicated funds from limited partners and invests growth-stage capital into US-headquartered healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. Beyond capital, the firm deploys a "Collaborative Capital" approach that bundles eight categories of hands-on operating support — growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization — into a bespoke investment structure tailored to each founder's needs. Galen has raised six dedicated funds totaling nearly $1 billion since 1990 and built a portfolio of more than 80 healthcare companies across Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.
Is Galen Partners a public or private company?
Galen Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Galen Partners founded?
Galen Partners was founded in 1990. It employs 11 to 50 people.
Where is Galen Partners based?
Galen Partners is headquartered in Stamford, United States, in the North America region.
How does Galen Partners make money?
Two revenue lines are on record. Healthcare growth equity fund management is the primary driver. The others are operating support and value creation services.
Who are Galen Partners's main competitors?
Broad incumbents on record are Arsenal Capital Partners and General Atlantic. Direct peers are Welsh, Carson, Anderson & Stowe, New Mountain Capital, Linden Capital Partners, Cressey & Company, Avista Capital Partners, Health Velocity Capital, Aquiline Capital Partners and Ascension Ventures.
Does Galen Partners have an API?
No public API is recorded for Galen Partners.
What industry is Galen Partners in?
Galen Partners's product category is Healthcare Growth Equity / Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525190 and its SIC code is 6282.